11:01:46 EST Tue 07 Feb 2023
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Diagnos Inc (3)
Symbol ADK
Shares Issued 69,474,151
Close 2022-03-15 C$ 0.245
Recent Sedar Documents

Diagnos joins CAN Health Network

2022-03-15 16:27 ET - News Release

Mr. Andre Larente reports

CAN HEALTH NETWORK AND QUEBEC-BASED DIAGNOS ANNOUNCE LIFE-CHANGING DIABETIC RETINOPATHY SCREENING PROGRAM PARTNERSHIP

Diagnos Inc. is the first Quebec-based organization to join the Coordinated Accessible National (CAN) Health Network. Through its strategic partner, Labtician Ophthalmics Inc., a Toronto-based company with eye care specialist customers across Canada, Diagnos's CARA (computer-assisted retina analysis) solution will help health care professionals in their day-to-day screening of diabetic patients by allowing them to monitor ocular health, ultimately helping to prevent vision loss in their patients.

Diabetic retinopathy is the leading cause of blindness, and early detection has been identified as the best preventative measure and solution. Patients who require these critical screenings often come up against barriers resulting in non-compliance, high costs or a missed diagnosis, leading to potentially life-altering vision loss. In particular, Diagnos's solution will help professionals identify patients who are overdue for a screening, ensuring diabetic retinopathy is caught early. This low-cost, non-invasive, state-of-the-art technology involves the use of a simple rear eye camera image, which quickly and effectively screens patients. Assessment results are then returned within a few minutes; saving both time and health care costs.

"Diagnos, a publicly traded company on the TSX Venture Exchange, is pleased to be part of the CAN Health Network," said Andre Larente, chief executive officer, Diagnos. "Our solution for screening diabetic patients uses artificial intelligence. The CARA application is approved by Health Canada and is in use today in hospitals and primary care clinics. This new local screening program will give accessibility to all patients in Canada to a fast and low-priced medical test."

Funded by the government of Canada, the CAN Health Network works with health care providers to identify their biggest challenges, and matches them with Canadian-made technology solutions. This integrated market model allows Canadian innovators to gain access to the health care market, and rapidly validate and scale their solution across the country and internationally.

"The CAN Health Network has been focused on accessing the Quebec marketplace to ensure a truly national scope and economic prosperity for all of Canada. Adding Diagnos and Labtician to the network is another great step in ensuring all Canadians have access to the best home-grown innovative health care technologies," said Dante Morra, chair, CAN Health Network.

"We are pleased to be working with CAN Health Network and Diagnos, a Canadian company based in Quebec, in addressing growing needs in the monitoring of diabetic patients," explains Labtician president Polydor Strouthos. "For over 60 years, we've been introducing innovative eye care products, solutions and resources for eye care professionals and their patients in the Canadian marketplace. Through our extensive network, we commercialize our high-quality value add eye care products as well as those of our forward-thinking partner companies in Canada and worldwide. We help companies through the complexities and nuances of Canadian and international markets, from prelaunch assistance and obtaining regulatory approval, to securing commercialization, and distribution channels."

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based of its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the United States Food and Drug Admnistration, CE (Europe), COFEPRIS (Mexico) and Saudi Food and Drug Authority (Saudi Arabia). Diagnos works with AI distributor Labtician Ophthalmics.

© 2023 Canjex Publishing Ltd. All rights reserved.